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Objectives: To analyze the cost of illness in the management of anemia among 
chronic kidney disease (CKD) patients on hemodialysis MethOds: Prospective 
observational study for a period 7 months was conducted after the approval of the 
protocol by the Ethics Committee. The patients on hemodialysis of both sexes aged 
between 18-75 years were enrolled in the management of anemia with erythropoi-
etin (EPO). The data relating to the cost and the number of units for EPO, Iron and 
Vitamin supplements were recorded and computed on weekly basis. Hemoglobin 
levels were recorded every month. The average cost incurred was calculated for 7 
months. Results: The number of subjects included in the study was 62 out of 96 
patients. The total number of EPO administered for 7 months was computed by 
adding all the doses for 7 months. On an average, each subject was administered 
27.44 of EPO doses equivalent to 113001.35 IU. The Iron supplements and vitamins 
constituted 15.54 doses and 32.6 doses respectively. The response of above-men-
tioned treatment reflected in raise in 8.67 g/dl hemoglobin levels per patient per 7 
months. The cost of EPO for doses administered was 111859.92 INR (1864.32 USD), 
Iron supplements 5594.4 INR (93.24 USD), Vitamin supplements 1587.83 INR (26.46 
USD). In addition, the laboratory charges for the measurement of hemoglobin levels 
were 325 INR (5.41 USD) per patient per 7 months. cOnclusiOns: Study reveals 
64.58% of patients were economically sound to undergo the treatment with EPO. 
Eighteen patients were covered by Employees’ State Insurance and 2 patients sup-
ported by their employers on reimbursement basis and the remaining 40 patients 
borne the expenses by themselves. The study revealed that the average cost in the 
management of anemia among chronic kidney disease patients on hemodialysis 
per patient per 7 months was 119367.15 INR (1989.45 USD).
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Objectives: Chronic kidney disease (CKD) represents a major public health concern 
with a great economic burden. The aim of the study is to estimate the mean annual 
social cost of a patient with CKD by stage (IV and V pre-dialyses) and cost component 
in Italy. MethOds: The cross sectional study included all adult outpatients that 
were in charge of the 14 main Hospital Centers in the Tuscany Region during 7 week. 
Direct medical costs have been estimated using tariff for laboratory test, diagnostic 
exams, visits and hospitalization and price for drugs. Non medical costs included 
the cost of diet, patients and caregivers travel expenses, formal and informal care. 
The loss of productivity of patients and caregivers have been estimated as indirect 
costs using the human capital approach. Costs are expressed as mean (± standard 
deviation) in Euro 2012. Results: 279 patients in stage IV and 205 patients in stage 
V have been enrolled. The estimated mean annual social cost of a patient with 
CKD were € 9,185 (± € 6,319) for stage IV and € 10,766 (± € 8,314) for stage V (p< 0,05). 
Direct medical costs were higher in stage V as compared to stage IV (€ 5,049 ± € 
4,017 versus € 3,840 ± € 4,042, p< 0,05). Direct non medical costs and indirect costs 
accounted respectively for 32% and 26% of the total social cost for CKD stage IV and 
for 26% and 27% of the total social cost for CKD stage V. In Italy the overall annual 
social cost of CKD stage IV and V was € 2,158,903,299 representing the 0.14% of the 
GDP. cOnclusiOns: Direct non medical costs and indirect costs represent the main 
component of the social cost of CKD. Patients, their families and the productivity 
system mainly sustain the burden of the disease.
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Objectives: To investigate the employee’s health insurance payment policy 
for stage-5 chronic renal failure patients treated with dialysis as well as stage1-4 
patients, analyze payment levels of the insurance and out-of-pocket medical 
expense. MethOds: This study involved 8809 stage-5 chronic renal failure cases 
treated with dialysis and 14472 stage1-4 cases in 6 provincial capital & vice-provincial 
cities (Shenyang, Nanjing, Qingdao, Zhengzhou, Chengdu, Urumchi).The actual claim 
data of medical expenses and medical care utilization from 2008 to 2010 were col-
lected. Descriptive analysis was applied to the data. The employee’s health insurance 
payment policies of the 6 cities were reviewed. Results: 1) All the cities provided 
both inpatient and outpatient medical expense payment for stage-5 chronic renal 
failure with dialysis, but for stage1-4 only 3 cities provided both inpatient and outpa-
tient payment while the others did not pay for outpatient.2) The actual payment levels 
of inpatient expense for dialysis ranged from 70% to 80%, and those of outpatient 
ranged from 70% to 90% in various cities. The out-of-pocket expense for inpatient 
and outpatient were US$839 and US$829,respectively. 3) In the 3 cities which pro-
vided both inpatient and outpatient payment for stage1-4 chronic renal failure, the 
actual payment levels for inpatient ranged from 64% to 77% and those of outpatient 
ranged from 61% to 75% . The out-of-pocket expense for inpatient and outpatient 
reached US$510 and US$464, respectively. cOnclusiOns: Generally,health insur-
ance for employees eased the economic burden of stage-5 patients with dialysis and 
made out-of-pocket expense acceptable. Provision of outpatient payment for stage1-4 
patients is necessary in lowering the economic burden and meeting the outpatient 
service demand of the patients. Therefore,the employee’s health insurance should 
strengthen medical service monitoring for dialysis,handle the catastrophic medical 
expense risk of stage-5 patients with extremely high medical expenses and provide 
outpatient payment for stage1-4 patients.
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controlling for age and gender effects on costs. Moreover, a propensity score match-
ing analysis was used to test for robustness of the results. Results: OAB patients 
caused additional annual costs of € 772 compared to non-OAB patients. Patients 
treated with Oxybutynin had the lowest additional costs (€ 660) while patients 
treated with Tolterodine yielded the highest additional costs (€ 1,049). In the special 
case of incontinence, patients treated with Solifenacin incurred the lowest addi-
tional costs (€ 1,242) and patients treated with Tolterodine the highest (€ 1,835). 
The lower treatment costs for Solifenacin are mainly driven by lower spending on 
medical aids, especially due to lower pad usage. All results are highly significant (p 
< 0.01) and propensity score matching produced similar findings. cOnclusiOns: 
This study compares the annual cost of six anticholinergics for the treatment of 
OAB and incontinence in patients 40 years of age or older in Germany. OAB patients 
treated with Oxybutynin and incontinent patients treated with Solifenacin have 
shown the lowest additional cost. For both patient groups Tolterodine is associated 
with the highest additional cost of treatment.
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Objectives: To determine the real-world dose equivalency of sevelamer hydro-
chloride/carbonate (SH/C) and lanthanum carbonate (LC) monotherapies, and 
compare the drug costs associated with various dosages of SH/C versus conver-
sion to LC. MethOds: Data were evaluated retrospectively for patients receiving 
hemodialysis in the US, who converted in either direction between SH/C and LC 
monotherapies, yet had similar phosphate (P) levels over the observation period. 
The study comprised a 90-day pre-conversion period followed by a 90-day post-
conversion period. Serum P and daily P binder doses were assessed across six 30-day 
periods. Primary comparisons were based on data from the last month of each 
treatment period to allow for clinical equilibration. Drug cost assessments were 
based on prescription fills and REDBOOK pricing (Sept 2013). Results: A total of 
303 patients met study criteria: 128 converted from SH/C (mean dose ~8200 mg/day) 
to LC (~3400 mg/day) and 175 converted from LC (~3800 mg/day) to SH/C (~8600 mg/
day). In the post-conversion, serum P ranged from 5.99±1.64 mg/dL to 6.43±1.87 mg/
dL in patients converting from SH/C to LC, and from 6.18±1.68 mg/dL to 6.51±1.92 
mg/dL in those converting from LC to SH/C. For combined patient cohorts, the overall 
dose equivalency of SH/C:LC was 2.27. Mean P binder costs were $1080±491/patient/
month with SH/C and $1006±513 with LC. Mean cost differences between pre- and 
post-conversion phases, in either direction, were –$74.20/patient/month (95%CI 
–141.80, –6.63; p< 0.05) in favor of LC. Cost differences between LC and SH/C were 
greatest (–$359; 95%CI –485, –260; p< 0.001) in favor of LC, in patients receiving > 7200 
mg SH/C daily (50.7% of patients). cOnclusiOns: Patients who converted between 
LC and SH/C monotherapies in either direction maintained similar P levels in both 
conversion phases. LC was 2.27 times as potent as SH/C on an mg-to-mg basis and 
was associated with significantly lower P binder costs.
PUK13
healTh care coSTS aMong PaTienTS Who conTinUe TheraPy or SWiTch 
anTiMUScarinic agenTS for overacTive Bladder
Ivanova J.1, Hayes-Larson E.1, Sorg R.A.1, Birnbaum H.G.2, Fitzmartin J.3, Berner T.3
1Analysis Group, Inc., New York, NY, USA, 2Analysis Group, Inc., Boston, MA, USA, 3Astellas 
Scientific and Medical Affairs, Inc., Northbrook, IL, USA
Objectives: To compare health care costs among patients who continued ther-
apy or switched antimuscarinic agents for overactive bladder (OAB). MethOds: 
Patients initiating antimuscarinic therapy from 1/1/2007-3/31/2012 diagnosed with 
OAB were identified from a large claims database of privately insured patients. 
Patients were required to have no antimuscarinic claims in the 12 months before 
their antimuscarinic initiation (baseline period), continuous coverage for ≥ 12 
months before and after antimuscarinic initiation, and age 18-64 years. Based on 
claims in the 6 months after antimuscarinic initiation, patients who continued 
index antimuscarinic therapy were categorized as persisters (n= 3,197), and patients 
with a claim for a non-index antimuscarinic agent (without a gap > 60 days after 
the end of index antimuscarinic treatment) were categorized as switchers (n= 828). 
The study index date was defined as the date of switching from index antimus-
carinic for switchers and a randomly assigned date (matching the distribution of 
time from initiation to switching) for persisters. All-cause and OAB-related costs 
(i.e., reimbursements to providers for medical and pharmacy claims) in the month 
prior to and 6 months after the index date were compared using generalized lin-
ear models controlling for baseline characteristics and baseline costs. Results: 
Persisters compared with switchers were older and had lower baseline costs. After 
controlling for baseline characteristics and costs, all-cause and OAB-related costs 
in both the month before and 6 months after the index date were significantly 
lower among persisters than switchers (1 month before: all-cause $1,222 vs. $1,759, 
OAB-related $142 vs. $170; 6 months after: all-cause $7,017 vs. $8,806, OAB-related 
$642 vs. $797; all p< 0.0001). cOnclusiOns: All-cause and OAB-related costs in the 
period immediately before and after switching were higher among patients who 
switched antimuscarinic therapies compared with patients who persisted on their 
index antimuscarinic therapy.
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